300171 Tofflon Science and Technology Group
- 13.95
- +0.20+1.45%
Tofflon Science and Technology Group News
Dongfulong (300171.SZ): Net profit of 64.6641 million yuan in the first quarter decreased by 72.01% year-on-year
Gelonghui, April 28 | Dongfulong (300171.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1.09 billion yuan, down 22.07% year on year; net profit attributable to shareholders of listed companies was 646.641 million yuan, down 72.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 598.18,600 yuan, down 73.44% year on year; basic earnings per share were 0.0850 yuan.
Dongfulong (300171.SZ) announced its 2023 annual results, net profit of 600 million yuan, a decrease of 29.10%
According to the Zhitong Finance App, Dongfulong (300171.SZ) released its 2023 annual report. During the reporting period, the company achieved revenue of 5.642 billion yuan, an increase of 3.15% over the previous year. Achieved net profit attributable to shareholders of listed companies of 600 million yuan, a year-on-year decrease of 29.10%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 557 million yuan, a year-on-year decrease of 28.57%. Basic earnings per share were $0.79. It is proposed to distribute a cash dividend of 2.4 yuan (tax included) for every 10 shares to all shareholders.
Dongfulong (300171.SZ): The company does not hold shares in Yizun Biotech
Gelonghui April 17 丨 Dongfulong (300171.SZ) said on the investor interactive platform that the company does not hold shares in Yizun Biotech and that Yizun Biotech has a cooperative relationship with the company.
Dongfulong (300171.SZ): Initial repurchase of 653,600 shares involving 9.5513 million yuan
Gelonghui, March 27, 丨 Dongfulong (300171.SZ) announced that on March 26, 2024, the company repurchased 653,600 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0859% of the company's current total share capital. The highest transaction price was 14.70 yuan/share, the minimum transaction price was 14.53 yuan/share, and the total transaction amount was RMB 955.12.52 million (excluding transaction fees).
Fulong Group, the main shareholder of Societe Generale Yinxi (000426.SZ), reduced its shares by 1.28%
Societe Generale Yinxi (000426.SZ) issued an announcement. The company recently received Chifeng Fulong, a shareholder holding more than 5% of the shares...
Express News | Eight Shanghai enterprises were approved as national enterprise technology centers in 2023
Express News | Shanghai Future Industry Biomanfacture Expert Committee established
Express News | Dongfulong: Professional technology serves biomedicine to help the development of human health
Dongfulong (300171.SZ): Plans to spend 50 million yuan to 100 million yuan to buy back the company's shares
Gelonghui, Feb. 6 | Dongfulong (300171.SZ) announced that the company plans to use its own funds to repurchase RMB common stock (A shares) shares issued by the company; to implement equity incentives or employee stock ownership plans. If the company fails to use it for these purposes within 36 months after the share repurchase is completed, the unused portion will be cancelled. Under the condition that the maximum repurchase price is 23.35 yuan/share (inclusive), the total number of shares that can be repurchased is estimated at RMB 10,000 (inclusive), the total number of shares that can be repurchased is estimated to be 4.282,600 shares, accounting for about 0.56% of the company's current total share capital; according to this repurchase
Dongfulong (300171.SZ): The actual controller has accumulated 0.23% increase in shares
Gelonghui, Feb. 5 | Dongfulong (300171.SZ) announced that as of the disclosure date of this announcement, the actual controller Mr. Zheng Xiaodong's plan to increase his holdings has been completed. From December 28, 2023 to February 2, 2024, Mr. Zheng Xiaodong increased his holdings of the company's shares by 1,770,000 shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.23% of the company's total share capital, and the increase in holdings was 30,025,652 yuan.
Dongfulong (300171): Formulation Division Highlights Customer Expansion and Strengthening
Key investment highlights Financial performance: Fluctuating demand, declining growth and profitability 2023Q1-Q3: achieved revenue of 4.325 billion yuan, an increase of 13.31% year on year; net profit to mother was 583 million yuan, a decrease of 3.48% year on year
Dongfulong (300171.SZ): Actual controller Zheng Xiaodong plans to increase the company's shares by no less than 30 million yuan
Gelonghui, December 27, 丨 Dongfulong (300171.SZ) announced that on December 27, 2023, the company received a “Notice Letter on the Share Increase Plan” from Mr. Zheng Xiaodong, the actual controller of the company. Mr. Zheng Xiaodong plans to increase his holdings of the company's shares through centralized bidding and other means within 6 months from the date of disclosure of the announcement. The amount of this increase is not less than RMB 30 million.
Tofulong (300171.SZ): The company's products have been used in the customer's synthetic biology business
Glonghui, December 26|Dongfulong (300171.SZ) Investor Interactive Platform stated that the company's bioprocess sector business mainly provides customers with various equipment, instruments, and consumables that meet the needs of customers in application scenarios such as chemical raw materials for small molecule drugs, raw materials extracted from traditional Chinese medicine, biological stock solutions for macromolecule drugs, and preparation of cell-gene therapy drugs. The company's products have already been used in the field of synthetic biology.
Research Report Nuggets: Huaxin Securities: Maintaining Tofulong's “Buy” Rating, Optimistic About Subsequent Product Release
Glonghui, December 8 | According to Huaxin Securities Research Report, Dongfulong (300171.SZ) is a leading domestic pharmaceutical equipment leader. Thirty years of industry accumulation have created strong manufacturing technology advantages, and the business has expanded into high-growth emerging fields such as life science, so it is optimistic about future product releases. Maintain a “buy” investment rating. As a pioneer in domestic pharmaceutical equipment going overseas, the company's overseas products are highly complex, there are many systematic orders, and outstanding profitability. In the first half of 2023, the gross margin of the company's overseas business reached 50.5%, achieving overseas revenue of 581 million yuan, with export sales accounting for 19.7% of revenue. As the company sells overseas products
Dongfulong (300171): Steady growth in revenue, promising expansion in overseas markets
Dongfulong announced the results announcement for the third quarter of 2023: in the first three quarters of 2023, it achieved operating income of 4.325 billion yuan, an increase of 13.31% over the previous year; net profit attributable to shareholders of listed companies was 583 million yuan, down from the previous year
Dongfulong (300171): Oriental Dragons in the upstream pharmaceutical industry have always grasped the boom track
Pharmaceutical innovation drives the development of upstream enterprises, and overseas markets are vast. Global pharmaceutical upstream leader Xianfa has completed comprehensive coverage of upstream pharmaceutical products. With its rich product categories, excellent performance, and perfect echelon layout, it has successfully gone overseas. Thermo Fly is in 2
Dongfulong (300171): Under the influence of macro factors, the profit side is under pressure, and the fund-raising project is progressing smoothly
Event description: On October 27, 2023, the company released its report for the third quarter of 2023. 2023Q1-Q3 achieved operating income of 4.325 billion yuan, an increase of 13.31% over the previous year; achieved net profit
Hyde Control (002184.SZ): Major cooperative enterprises in the intelligent pharmaceutical equipment industry include Dongfulong, Chutian Technology, Zhejiang Tailin, and Xinhua Medical
On October 31, Gelonghui, Hyde Control (002184.SZ) stated on the investor interactive platform that the industrial informatization business, one of the company's main businesses, mainly provides safe and reliable automation, information product services, and automation and information technology integration system solutions for users in pharmaceutical and other industries. The company's main partners in the intelligent pharmaceutical equipment industry include Dongfulong, Chutian Technology, Zhejiang Tailin, and Xinhua Medical.
Dongfulong (300171): Actively developing customers and looking forward to order resumption
Event: October 26, 2023, the company released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved operating income of 4.325 billion yuan, an increase of 13.31% over the previous year; net profit of 5.83
Dongfulong (300171.SZ) released results for the first three quarters, with net profit of 583 million yuan, a year-on-year decrease of 3.48%
Dongfulong (300171.SZ) released its report for the third quarter of 2023. The company achieved revenue of 43 in the first three quarters...
Analysis
Price Target
No Data
